FIG 2.

Change in spleen volume by local review after treatment with pelabresib and ruxolitinib. (A) Waterfall plot of percentage change from baseline spleen volume at week 24 by local review. (B) Mean percentage change from baseline spleen volume over time. Patients were evaluable for assessment of spleen volume reduction at week 24 if they had a week 24 assessment by the data cutoff or discontinued without a week 24 assessment at any time. Five patients who discontinued before week 24 spleen assessment were considered nonresponders. Spleen volume median percentage change includes patients with available spleen volume assessment for the corresponding time points. Five patients were nonevaluable at week 48 assessment as they had not yet reached week 48, and 18 patients who discontinued before week 48 were included as nonresponders. For SVR35 at week 24, 95% CIs were 57 to 78. SD, standard deviation; SVR35, ≥ 35% reduction in spleen volume from baseline.